Skip to main content
. 2018 Apr 30;128(6):2325–2338. doi: 10.1172/JCI96711

Figure 3. ONC201 inhibits metastasis in vivo.

Figure 3

(A) Metastasis imaging by gross analysis (top panels) and histology of liver in HT29 xenograft–bearing mice treated with vehicle or 100 mg/kg ONC201 for 3 weeks (middle; original magnification, ×10). Bottom: MRI of lung of HT29 subcutaneous xenograft mouse treated with vehicle after 4 weeks following inoculation. The panels show imaging of 1 vehicle-treated mouse from different MRI viewpoints. The tumor is indicated by a blue arrow. (B) HCT116-GFP tumor lesions from mice with primary tumor surgically removed and tumor metastases allowed to grow for 1–3 weeks before treatment, as identified by fluorescence imaging for vehicle or 100 mg/kg ONC201. (C) Estimated size by CT imaging before and after treatment in ONC201- and vehicle-treated in HT29 xenograft cohorts. (D) Representative CT images of HT29 xenograft mice treated through tail vein injection. Yellow: tumor burden; green: lung tissue. Same mouse, day 0 and day 14. For mouse tumor studies, n = 6 mice in subcutaneous HT29 in A and tail vein HT29 in C and D; n = 4 in HCT116-GPF. In C, 2 vehicle-treated mice died before end of study. All samples were harvested 4 weeks after treatment began unless otherwise indicated. *P < 0.05 compared with the vehicle, 2-side Wilcoxon’s rank-sum test. Data represent mean ± SD.